Longeveron Inc. (LGVNR)

Compare

0.0005

-0.0003

(-37.50%)

As of September 21 at 3:51:25 PM EDT. Market Open.

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease

Nataliya Agafonova Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron Planned single, pivotal Phase 2/3 clinical trial, if positive, acceptable for Biological License Application (BLA) submission for Alzheimer’s diseaseAlignment with FDA on proposed trial study design, population and endpointsInitiation of planned pivotal Phase 2/3 clinical trial anticipated in 2H 2026, contingent upon obtaining non-dilutive funding and/or partnering supportLaromestrocel (Lomecel-B™) has received FDA Re

GlobeNewswire 20 days ago

LGVN

LGVNR
-37.50%
LGVN Announces Positive Alzheimer’s News

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) is a company that should be getting more attention from investors and the just released annual results again proved that point. LGVN has made substantial progress with its signature treatment, Lomecel-B, in treating both HLHS and Alzheimer's Disease and we suggest investors take a look at this stock

Zacks Small Cap Research 20 days ago

LGVNR
-37.50%
Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease

Nataliya Agafonova Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Chairman, Longeveron Phase 2a results demonstrated laromestrocel (Lomecel-B™) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer’s diseaseThis encouraging clinical trial data adds to the body of evidence supporting the safety of single and multiple doses of laromestrocel (Lomecel-B™) treatment

GlobeNewswire 29 days ago

LGVN

LGVNR
-37.50%
Longeveron® to Present at the 37th Annual Roth Conference

MIAMI, March 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the 37th Annual Roth Conference taking place March 17-18, 2025. Details for the Company’s fireside chat: Date:Tuesday, March 18, 2025 Time:9:00 – 9:25 a.m. PT The webcast for this conference presentation may be accessed at the “Even

GlobeNewswire last month

LGVN

LGVNR
-37.50%
LGVN Well Positioned for Critical 2025

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) is a company that should be getting more attention from investors and the just released annual results again proved that point. LGVN has made substantial progress with its signature treatment, Lomecel-B, in treating both HLHS and Alzheimer's Disease and we suggest investors take a look at this stock

Zacks Small Cap Research last month

LGVNR
-37.50%
Analysts Expect Breakeven For Longeveron Inc. (NASDAQ:LGVN) Before Long

With the business potentially at an important milestone, we thought we'd take a closer look at Longeveron Inc.'s...

Simply Wall St. last month

LGVN

LGVNR
-37.50%
Longeveron Full Year 2024 Earnings: Beats Expectations

Longeveron ( NASDAQ:LGVN ) Full Year 2024 Results Key Financial Results Revenue: US$2.39m (up 237% from FY 2023). Net...

Simply Wall St. last month

LGVN

LGVNR
-37.50%
Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Wa'el Hashad Wa'el Hashad, Chief Executive Officer, Longeveron Inc. Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more than 90% enrollment and is expected to complete enrollment in the second quarter of 2025Lomecel-B™ Biological License Application (BLA) submission for full traditional approval anticipated in 2026, if ELPIS II is successfulFDA meet

GlobeNewswire last month

LGVN

LGVNR
-37.50%
Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025

MIAMI, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report full-year 2024 financial results and provide a business update on Friday, February 28, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast

GlobeNewswire last month

LGVN

LGVNR
-37.50%
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting com

GlobeNewswire last month

HGRAF

AEMD

GOSS
Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Wa'el Hashad Wa'el Hashad, CEO, Longeveron Cellular therapy Lomecel-B™ has been granted an International Non-proprietary Name (INN) of “laromestrocel” on the INN List issued by the World Health Organization (WHO)Lomecel-B™ is a proprietary, scalable, allogeneic cellular therapy being evaluated in Alzheimer’s disease and hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan indicationLomecel-B™ first cellular therapeutic candidate to receive U.S. FDA Regenerative Medicine Ad

GlobeNewswire last month

LGVN

LGVNR
-37.50%
Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025

MIAMI, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the Emerging Growth Virtual Conference taking place February 18-19, 2025. Details for the Company’s presentation: Date:February 19, 2025Time:3:10 – 3:20 p.m. ET The webcast for this conference presentation may be accessed at the “Eve

GlobeNewswire last month

LGVN

LGVNR
-37.50%
Longeveron to Present at Biotech Showcase 2025

MIAMI, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Wa’el Hashad, Chief Executive Officer, will give a corporate presentation at Biotech Showcase, being held January 13-15, 2025. Details for the Company’s presentation: Date:Tuesday, January 14, 2025Time:4:00 – 4:30 p.m. PT The webcast for this conference pr

GlobeNewswire 3 months ago

LGVN

LGVNR
-37.50%
Longeveron initiated with a Buy at Roth MKM

Roth MKM last night initiated coverage of Longeveron (LGVN) with a Buy rating and $10 price target The firm says its investment thesis is driven by the 100% transplant-free survival benefits at the end of five years delivered by Lomecel-B in hypoplastic left heart syndrome. HLHS presents a grave danger to infant survival despite three-stage palliative surgeries, As previously reported, Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

TipRanks 3 months ago

LGVN

LGVNR
-37.50%
Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

MIAMI, Dec. 04, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Conference on December 4 & 5, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa

GlobeNewswire 4 months ago

UCAR

OPWEF

BIXT
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

MIAMI, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the Emerging Growth Virtual Conference taking place December 4-5, 2024. Details for the Company’s presentation: Date:December 5, 2024Time:12:00 – 12:30 p.m. ET The webcast for this conference presentation may be accessed at the “Even

GlobeNewswire 4 months ago

LGVN

LGVNR
-37.50%
We're Keeping An Eye On Longeveron's (NASDAQ:LGVN) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. 4 months ago

LGVN

LGVNR
-37.50%
LGVN Highlights Potential Groundbreaking Treatments

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) is a company that should be getting more attention from investors. LGVN has made substantial progress with its signature treatment, Lomecel-B, in treating both HLHS and Alzheimer's Disease and we suggest investors take a look at this stock before more good news comes out—such as what happened recently.

Zacks Small Cap Research 4 months ago

LGVNR
-37.50%
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update

Wa'el Hashad Wa'el Hashad, CEO, Longeveron Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS has achieved more than 80% enrollmentPositive Type C meeting with U.S. FDA confirmed ELPIS II is pivotal and, if positive, acceptable for Biological License Application (BLA) submission for full traditional approvalPositive data from the Phase 2a clinical trial (CLEAR MIND) evaluating Lomecel-B™ in Alzheimer’s disease presented in Featured Research Oral Presentation

GlobeNewswire 4 months ago

LGVN

LGVNR
-37.50%
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing, and Controls (CMC), effective December 2, 2024. In this role, he will lead the Company’s technological and manufacturing strategies. “We a

GlobeNewswire 4 months ago

LGVN

LGVNR
-37.50%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Longeveron Inc. (LGVNR)

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease

LGVN Announces Positive Alzheimer’s News

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease

Longeveron® to Present at the 37th Annual Roth Conference

LGVN Well Positioned for Critical 2025

Analysts Expect Breakeven For Longeveron Inc. (NASDAQ:LGVN) Before Long

Longeveron Full Year 2024 Earnings: Beats Expectations

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025

Longeveron to Present at Biotech Showcase 2025

Longeveron initiated with a Buy at Roth MKM

Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

We're Keeping An Eye On Longeveron's (NASDAQ:LGVN) Cash Burn Rate

LGVN Highlights Potential Groundbreaking Treatments

Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)